IP Library › Granted Patent US 11,746,161
Granted Patent B2
US 11,746,161 · App. 17/125,263 · Granted Sep 5, 2023

Antibodies that specifically bind PD-1 and methods of use

Inventors: Qiang Chen (San Diego, CA); Suzanne Cole (Spring House, PA); Karen Duffy (Spring House, PA); Yanxia Guo (Spring House, PA); Debra Gardner (Spring House, PA); Damon Hamel (San Diego, CA); Shannon Hitchcock (Spring House, PA); Ann Lacombe (San Diego, CA); Jinquan Luo (Spring House, PA); Ravi Malaviya (Spring House, PA); Yevgeniya Orlovsky (Spring House, PA); Pejman Soroosh (San Diego, CA); Melissa Swiecki (Spring House, PA); Deepti Wilkinson (San Diego, CA)
Assignee: Janssen Biotech, Inc.
C07K16/40A61K39/3955A61P37/06C07K16/065C07K16/18C07K16/2818C12N15/00A61K2039/505A61K2039/57C07K2317/24C07K2317/33C07K2317/73C07K2317/732C07K2317/75C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,746,161
App. No.
17/125,263
Granted
Sep 5, 2023
Kind
B2
Abstract

Antibodies that specifically bind PD-1 or antigen binding fragments thereof, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of an inflammatory or immune disorder.

Claims (40)

1. An isolated polynucleotide comprising one or more nucleotide sequence(s):

a) encoding the heavy chain variable region (VH) of SEQ ID NO: 118;

b) encoding the light chain variable region (VL) of SEQ ID NO: 119;

c) encoding the VH of SEQ ID NO: 118 and the VL of SEQ ID NO: 119;

d) encoding the VH of SEQ ID NO: 10;

e) encoding the VL of SEQ ID NO: 16;

f) encoding the VH of SEQ ID NO: 10 and the VL of SEQ ID NO: 16; or

g) comprising the polynucleotide sequence of SEQ ID NO: 13, 19, 132 or 133.

2. A vector comprising the isolated polynucleotide of claim 1 .

3. A culture comprising a host cell comprising the vector of claim 2 .

4. The culture of claim 3 , wherein the host cell is a eukaryotic cell, a prokaryotic cell, a CHO cell, a HEK293 cell or a hybridoma.

5. A method of making an antibody or antigen binding fragment thereof, comprising culturing the culture of claim 4 under conditions that the antibody or the antigen binding fragment thereof is expressed, and isolating the antibody or the antigen binding fragment thereof.

6. A polynucleotide comprising one or more nucleotide sequence(s):

a. encoding a heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 2, a HCDR2 of SEQ ID NO: 165, a HCDR3 of SEQ ID NO: 4, a light chain complementarity determining region 1 (LCDR1) of SEQ ID NO:166, a LCDR2 of SEQ ID NO: 6 and a LCDR3 of SEQ ID NO: 7, respectively;

b. encoding a HCDR1 of SEQ ID NO: 2, a HCDR2 of SEQ ID NOs: 3, 145, 146 or 147, a HCDR3 of SEQ ID NO: 4, a LCDR1 of SEQ ID NOs: 5, 148 or 149, a LCDR2 of SEQ ID NO: 6 and a LCDR3 of SEQ ID NO: 7, respectively;

c. encoding a HCDR1 of SEQ ID NO: 2, a HCDR2 of SEQ ID NO: 3, a HCDR3 of SEQ ID NO: 4, a LCDR1 of SEQ ID NO: 5, a LCDR2 of SEQ ID NO: 6 and a LCDR3 of SEQ ID NO: 7, respectively;

d. encoding a HCDR1 of SEQ ID NO: 2, a HCDR2 of SEQ ID NO: 145, a HCDR3 of SEQ ID NO: 4, a LCDR1 of SEQ ID NO: 5, a LCDR2 of SEQ ID NO: 6 and a LCDR3 of SEQ ID NO: 7, respectively;

e. encoding a HCDR1 of SEQ ID NO: 2, a HCDR2 of SEQ ID NO: 146, a HCDR3 of SEQ ID NO: 4, a LCDR1 of SEQ ID NO: 5, a LCDR2 of SEQ ID NO: 6 and a LCDR3 of SEQ ID NO: 7, respectively;

f. encoding a HCDR1 of SEQ ID NO: 2, a HCDR2 of SEQ ID NO: 147, a HCDR3 of SEQ ID NO: 4, a LCDR1 of SEQ ID NO: 5, a LCDR2 of SEQ ID NO: 6 and a LCDR3 of SEQ ID NO: 7, respectively;

g. encoding a HCDR1 of SEQ ID NO: 2, a HCDR2 of SEQ ID NO: 3, a HCDR3 of SEQ ID NO: 4, a LCDR1 of SEQ ID NO: 148, a LCDR2 of SEQ ID NO: 6 and a LCDR3 of SEQ ID NO: 7, respectively;

h. encoding a HCDR1 of SEQ ID NO: 2, a HCDR2 of SEQ ID NO: 3, a HCDR3 of SEQ ID NO: 4, a LCDR1 of SEQ ID NO: 149, a LCDR2 of SEQ ID NO: 6 and a LCDR3 of SEQ ID NO: 7, respectively;

i. encoding a HCDR1 of SEQ ID NO: 2, a HCDR2 of SEQ ID NO: 145, a HCDR3 of SEQ ID NO: 4, a LCDR1 of SEQ ID NO: 148, a LCDR2 of SEQ ID NO: 6 and a LCDR3 of SEQ ID NO: 7, respectively;

j. encoding a HCDR1 of SEQ ID NO: 2, a HCDR2 of SEQ ID NO: 146, a HCDR3 of SEQ ID NO: 4, a LCDR1 of SEQ ID NO: 148, a LCDR2 of SEQ ID NO: 6 and a LCDR3 of SEQ ID NO: 7, respectively;

k. encoding a HCDR1 of SEQ ID NO: 2, a HCDR2 of SEQ ID NO: 147, a HCDR3 of SEQ ID NO: 4, a LCDR1 of SEQ ID NO: 148, a LCDR2 of SEQ ID NO: 6 and a LCDR3 of SEQ ID NO: 7, respectively;

l. encoding a HCDR1 of SEQ ID NO: 2, a HCDR2 of SEQ ID NO: 145, a HCDR3 of SEQ ID NO: 4, a LCDR1 of SEQ ID NO: 149, a LCDR2 of SEQ ID NO: 6 and a LCDR3 of SEQ ID NO: 7, respectively;

m. encoding a HCDR1 of SEQ ID NO: 2, a HCDR2 of SEQ ID NO: 146, a HCDR3 of SEQ ID NO: 4, a LCDR1 of SEQ ID NO: 149, a LCDR2 of SEQ ID NO: 6 and a LCDR3 of SEQ ID NO: 7, respectively; or

n. encoding a HCDR1 of SEQ ID NO: 2, a HCDR2 of SEQ ID NO: 147, a HCDR3 of SEQ ID NO: 4, a LCDR1 of SEQ ID NO: 149, a LCDR2 of SEQ ID NO: 6 and a LCDR3 of SEQ ID NO: 7, respectively.

7. A vector comprising the polynucleotide of claim 6 .

8. A culture comprising a host cell comprising the vector of claim 7 .

9. The culture of claim 8 , wherein the host cell is a eukaryotic cell, a prokaryotic cell, a CHO cell, a HEK293 cell or a hybridoma.

10. A method of making an antibody or antigen binding fragment thereof, comprising culturing the culture of claim 9 under conditions that the antibody or the antigen binding fragment thereof is expressed, and isolating the antibody or the antigen binding fragment thereof.

11. An isolated polynucleotide comprising one or more nucleotide sequence(s):

a. encoding the antibody heavy chain (HC) of SEQ ID NO: 22;

b. encoding the antibody light chain (LC) of SEQ ID NO: 28;

c. encoding the HC of SEQ ID NO: 22 and the LC of SEQ ID NO: 28; or

d. comprising the polynucleotide sequence of SEQ ID NO: 25, 31, 134 or 135.

12. A vector comprising the isolated polynucleotide of claim 11 .

13. A culture comprising a host cell comprising the vector of claim 12 .

14. The culture of claim 12 , wherein the host cell is a eukaryotic cell, a prokaryotic cell, a CHO cell, a HEK293 cell or a hybridoma.

15. A method of making an antibody or antigen binding fragment thereof, comprising culturing the culture of claim 14 under conditions that the antibody or the antigen binding fragment thereof is expressed, and isolating the antibody or the antigen binding fragment thereof.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2023
From: MALAVIYA, RAVI
To: CILAG AG
Reel/Frame 062852/0975 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2023
From: CILAG AG
To: JANSSEN BIOTECH, INC.
Reel/Frame 062853/0115 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2023
From: CHEN, QIANG; HAMEL, DAMON; LUO, JINQUAN
To: CENTOCOR RESEARCH & DEVELOPMENT, INC.
Reel/Frame 062853/0396 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2023
From: CENTOCOR RESEARCH & DEVELOPMENT, INC.
To: JANSSEN BIOTECH, INC.
Reel/Frame 062853/0583 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2023
From: COLE, SUZANNE; GARDNER, DEBRA; GUO, YANXIA; HITCHCOCK, SHANNON; SOROOSH, PEJMAN; SWIECKI, MELISSA; WILKINSON, DEEPTI
To: JANSSEN RESEARCH & DEVELOPMENT, LLC
Reel/Frame 062854/0095 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2023
From: JANSSEN RESEARCH & DEVELOPMENT, LLC
To: JANSSEN BIOTECH, INC.
Reel/Frame 062854/0189 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2023
From: DUFFY, KAREN; LACOMBE, ANN; ORLOVSKY, YEVGENIYA
To: JANSSEN BIOTECH, INC.
Reel/Frame 062854/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2022
From: CHEN, QIANG; COLE, SUZANNE; DUFFY, KAREN; GARDNER, DEBRA; GUO, YANXIA; HAMEL, DAMON; HITCHCOCK, SHANNON; LACOMBE, ANN; LUO, JINQUAN; MALAVIYA, RAVI; ORLOVSKY, YEVGENIYA; SOROOSH, PEJMAN; SWIECKI, MELISSA; WILKINSON, DEEPTI
To: JANSSEN BIOTECH, INC.
Reel/Frame 059034/0277 →
Continuity (5)
Division 15997148 · Jun 4, 2018
Provisional Application 62673185 · May 18, 2018
Provisional Application 62648114 · Mar 26, 2018
Provisional Application 62515188 · Jun 5, 2017
Related Publication 20210102000A1 · Apr 8, 2021
Cited By (4)
US 12,227,567 US 12,281,166 US 12,497,458 US 12,742,010